Lumakras is approved for use in adults with KRAS G12C-mutated non-small cell lung cancer
Efficacy data revealed 40 percent response rate, median response duration of 11.1 months
<p style="margin-left: 20px;">Progression-free survival significantly longer with tislelizumab plus chemotherapy versus chemotherapy alone
Current approval of the once-daily tablet indicated for patients who have undergone complete tumor removal
Increased risks persist beyond six months for patients with lung cancer receiving PD1i and with malignant melanoma receiving CTLA-4i<strong></strong>
Interim analysis shows risk for disease progression or death lower for first-line therapy with lorlatinib versus crizotinib
Guidelines reduce postoperative opioid prescribing but may result in inadequate pain control for some
However, no significant difference in mortality found between remdesivir and placebo groups
Most older adults taking multiple medications have never had a comprehensive medication review
No reductions seen in 28-day mortality or duration of hospital stay in COVID-19 with lopinavir-ritonavir